Robin Harper Cowie, who holds the roles of Chief Financial Officer, Secretary, and Treasurer at Biodesix INC (NASDAQ:BDSX), executed a sale of 535 common shares on February 23, 2026. The proceeds from the transaction were approximately $6,834, reflecting a weighted average sale price of $12.7756 per share. Individual sale prices recorded for the block ranged from $12.58 to $13.16.
This sale came three days after Cowie exercised options on February 20, 2026, resulting in the acquisition of 1,469 shares of Biodesix common stock. Those newly obtained shares were received via restricted stock units.
Market context for the transaction shows that Biodesix shares have gained 87.79% year-to-date. However, data from InvestingPro indicates the company remained unprofitable over the trailing twelve months. Investors seeking deeper analysis can consult BDSX's Pro Research Report, which is listed among more than 1,400 reports available on InvestingPro.
Separately, Biodesix disclosed preliminary financial results for the fourth quarter and the full year 2025 that exceeded analyst expectations and the company’s own raised guidance. The company reported fourth-quarter revenue of $28.8 million, a 41% increase compared with the same quarter a year earlier. For the full year, Biodesix estimated revenue at $88.5 million, representing a 24% year-over-year increase. That full-year estimate surpassed the company’s previously raised guidance range of $84 million to $86 million.
Alongside top-line growth, the company noted that it achieved EBITDA profitability for 2025. The combination of stronger-than-expected revenue and positive EBITDA marks a notable change in the company’s financial profile for the reporting period.
The timing of Cowie’s sale relative to the options exercise and the company’s preliminary results provides a compact sequence of insider activity and corporate performance updates within a short window of late February 2026. The disclosed figures and filings present a mixed picture for stakeholders: accelerating revenue and EBITDA improvement on one hand, and continuing trailing-year unprofitability per InvestingPro on the other.
Readers and market participants who wish to review further analysis or model projections can reference BDSX’s Pro Research Report available through InvestingPro.